HSBC's base case target suggests 10 per cent upside over the prevailing stock price. Its bull case target suggests 40 per ...

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

Biocon's shares surged over 7% on January 14, 2025, after HSBC upgraded its rating to 'Buy' with a target price of ₹430, ...

With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...

According to reports, HSBC said that Biocon is well-placed for an operational turnaround, driven by key biosimilar launches ...

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

After the clearance from US drugs regulator, Motilal Oswal has upgraded Biocon to 'buy' with a target price of Rs 430 apiece.

Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated.

Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and ...

Shares of Biocon were in high demand on Monday after the pharmaceutical company's subsidiary Biocon Biologics' Johor Bahru ...

Motilal Oswal (MOSL) has reiterated its "Buy" rating on HCL Technologies, setting a target price of Rs 2,400, which implies a ...

Analysts said that assuming a $700 million market size for gAspart, Biocon can see US sales worth $25 million and $50 million ...